|
Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine Clinical research trials and Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine. Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine clinical trial. Participants frequently obtain the most expert healthcare available for their Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine  Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine
Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine
For Condition: HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: To determine if the pharmacokinetics of high doses of zidovudine (AZT) (that is, how fast AZT reaches the blood, what concentration of AZT is attained in the blood, and how long AZT remains in the blood) changes from day to day in the same patient. Also to determine whether the pharmacokinetics of AZT is changed when trimethoprim/sulfamethoxazole (SMX/TMP) is given at the same time, or whether the pharmacokinetics of SMX/TMP is altered by AZT given at the same time. AZT has been effective in treating HIV infection in some patients with AIDS, and SMX/TMP is an antibiotic combination which is useful in preventing or treating Pneumocystis carinii pneumonia (PCP). It is important to know how drugs interact in patients because addition of a second drug may change the speed at which a drug is eliminated from the body, and cause increased toxic effects or decreased therapeutic effects.
Details: AZT has been effective in treating HIV infection in some patients with AIDS, and SMX/TMP is an antibiotic combination which is useful in preventing or treating Pneumocystis carinii pneumonia (PCP). It is important to know how drugs interact in patients because addition of a second drug may change the speed at which a drug is eliminated from the body, and cause increased toxic effects or decreased therapeutic effects. Patients with HIV infection take AZT every 4 hours and/or SMX/TMP every 8 hours by mouth for 4 days as outpatients and then come into the clinical research center for 2 days of studies. On day 5 the final dose of medicine is given orally SMX/TMP or by intravenous infusion (AZT). Blood samples are drawn 10-20 times over a period of 12 hours and urine is collected for 36 hours. Concentrations of the drugs in the blood and urine samples are determined. This sequence is repeated twice, so that each patient takes AZT alone, SMX/TMP alone, and the combination of AZT and SMX/TMP over a period of about 3 weeks. Patients may be included in the study if they are asymptomatic, or have been diagnosed with ARC or AIDS, but not if they have PCP or any other severe opportunistic infection.
Eligibility:
Study Type: Interventional, Treatment, Open Label
Minimum Age/Maximum Age: 18 Years/50 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Prior Medication: Allowed: - Zidovudine (AZT) for patients with AIDS. - AIDS related complex (ARC). The presence of any one of the following findings within 12 months prior to entry and the absence of a concurrent illness or condition other than HIV infection to explain the findings: - Fever of > 38.5 degrees C persisting for longer than 3 weeks. - Involuntary weight loss of > 15 lbs. or > 10 percent of baseline noted in a 120-day period prior to evaluation. - Diarrhea (> 2 liquid stools per day) persisting for longer than 1 month. - History of clinical diagnosis of oral candidiasis or hairy leukoplakia. - Patients who have AIDS-associated opportunistic infections or tumors. - Patients eligible for AZT under the labeling. - A positive HIV antibody test. Exceptions will be made for patients with a previously positive HIV antibody test with progressive disease and patients where virus isolation has been made. - Patient with stable Kaposi's sarcoma, mild herpes infection, mild or stable depression, asymptomatic or mild cytomegalovirus or Epstein-Barr virus infection, or a hepatitis B virus carrier state will be acceptable for study. - A life expectancy of at least 3 months. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: - Severe ongoing opportunistic infections including Pneumocystis carinii pneumonia (PCP), cryptococcal or toxoplasmosis meningo-encephalitis, disseminated herpes simplex or herpes zoster. - Significant diarrhea at entry ( > 1 watery stool per day). Concurrent Medication: Excluded: - Phenytoin. Prior Medication: Excluded within 30 days of study entry: - Other antiretroviral agents or immunomodulating agents. - Patient has demonstrated prior sensitivity or has experienced significant adverse effects during prior therapy with the drugs to be used in the study. - Patient cannot abstain from alcohol or any other drugs, including nonprescription medication, during the study period.
Total Enrollment: 10
Location and Contact Information:
Overall Study Official:
PtachcinskiR, Study Chair,
Univ of Pittsburgh Med School
Pittsburgh, Pennsylvania,
United States
Additional Information:
Study ID Numbers: ACTG 037;
Study Start Date:
Record last reviewed: October 1991
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000734
Other Hiv Infections Studies:
1. Evaluation of the Interaction Between Acetaminophen and Zidovudine
2. A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)
3. Setting up a Blood Bank for Gene Therapy in HIV-Infected Infants
4. Atazanavir for HIV Infected Individuals: An Early Access Program
5. Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP
Related Studies:
Other HIV Infections Clinical Trials
Other Pennsylvania Clinical Trials
Other Pittsburgh Clinical Trials
Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine
|
|
|
|
|
|
|
|
